Valuation: Penumbra, Inc.

Market Cap 12.88B 11.12B 10.43B 9.5B 17.87B 1,232B 18.11B 122B 47.92B 617B 48.36B 47.31B 2,053B P/E 2026 *
74.2x
P/E 2027 * 53.4x
Enterprise Value 12.43B 10.73B 10.07B 9.17B 17.25B 1,189B 17.49B 118B 46.26B 596B 46.68B 45.67B 1,981B EV / Sales 2026 *
7.79x
EV / Sales 2027 * 6.75x
Free-Float
97.11%
Yield 2026 *
-
Yield 2027 * -
1 day+0.03%
1 week+0.35%
Current month+1.85%
1 month+2.77%
3 months+0.18%
6 months-4.08%
Current year+5.22%
1 week 325.25
Extreme 325.25
328.11
1 month 315.7
Extreme 315.7
328.11
Current year 290
Extreme 290
362.41
1 year 221.26
Extreme 221.26
362.41
3 years 148
Extreme 148
362.41
5 years 114.86
Extreme 114.865
362.41
10 years 56.05
Extreme 56.05
362.41
Manager TitleAgeSince
Chief Executive Officer 64 2004-06-20
President 41 2025-08-31
Director of Finance/CFO 54 2019-12-01
Director TitleAgeSince
Chairman 64 2014-12-31
Chairman 64 2004-12-31
Director/Board Member 59 2015-03-31
Date Insider Type Main position Quantity % Market Cap.
2/13/26 Free

Founder

589 0.0015%
2/13/26 Free

Director

589 0.0015%
2/13/26 Free

General Counsel

5,742 0.0146%
Change 5-day change 1-year change 3-year change Capi.($)
+0.04%+0.35%+28.11%+28.29% 12.88B
-0.17%+0.21%+17.16%+29.67% 6.88B
+5.91%+11.22%+55.30%+51.32% 6.46B
-3.80%-0.82% - - 5.66B
-1.23%+3.18%-27.67%+50.65% 4.56B
-0.64%-3.95%-26.40%-23.93% 3.91B
+3.45%+1.21%+44.91%-44.38% 1.97B
-1.98%-0.92%+58.37%-6.27% 1.71B
-0.77%-10.86%-34.06%+130.80% 1.55B
-1.27%+1.35%-28.24%-41.30% 1.34B
Average -0.11%+0.08%+9.72%+19.43% 4.69B
Weighted average by Cap. +0.09%+0.96%+17.10%+26.33%

Financials

2026 *2027 *
Net sales 1.6B 1.38B 1.29B 1.18B 2.21B 153B 2.24B 15.15B 5.94B 76.42B 5.99B 5.86B 254B 1.8B 1.55B 1.46B 1.33B 2.5B 172B 2.53B 17.09B 6.7B 86.21B 6.76B 6.61B 287B
Net income 176M 152M 143M 130M 245M 16.87B 248M 1.68B 656M 8.45B 662M 648M 28.11B 242M 209M 196M 179M 336M 23.17B 341M 2.3B 902M 11.61B 910M 890M 38.61B
Net Debt -447M -386M -362M -330M -620M -42.74B -629M -4.24B -1.66B -21.41B -1.68B -1.64B -71.23B -729M -629M -590M -538M -1.01B -69.67B -1.02B -6.92B -2.71B -34.9B -2.74B -2.68B -116B
Logo Penumbra, Inc.
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada, Australia and Singapore, as well as through distributors in select international markets.
Employees
4,700
Date Price Change Volume
26-08-17 US$327.10 +0.02% 45,376
26-08-14 US$327.02 +0.08% 251,610
26-08-13 US$326.75 +0.05% 209,553
26-08-12 US$326.58 +0.09% 230,043
26-08-11 US$326.28 +0.09% 240,396
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
16
Last Close Price
327.02USD
Average target price
361.83USD
Spread / Average Target
+10.65%

Quarterly revenue - Rate of surprise